Document Detail


Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.
MedLine Citation:
PMID:  23205024     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: With diminishing antimicrobial potency, the choice of effective empirical therapy has become more challenging. Thus, the pharmacodynamic evaluation of potential therapies is essential to identify optimal agents, doses and administration strategies.
METHODS: Monte Carlo simulation was conducted for standard and/or prolonged infusion regimens of cefepime, ceftazidime, ceftriaxone, ciprofloxacin, doripenem, ertapenem, meropenem and piperacillin/tazobactam. Minimum inhibitory concentrations were obtained for Escherichia coli (n=64 respiratory isolates), Enterobacter cloacae (n=53), Klebsiella pneumoniae (n=75) and Pseudomonas aeruginosa (n=273) throughout Canada. The cumulative fraction of response (CFR) was calculated using bactericidal targets for each regimen against each species. A CFR ≥90% was defined as optimal.
RESULTS: All cefepime, doripenem, ertapenem and meropenem regimens achieved optimal exposures against Enterobacteriaceae, whereas target attainment was organism and dose dependent for the other agents. Prolonged infusion doripenem and meropenem 1 g and 2 g every 8 h, along with standard infusion doripenem and meropenem 2 g every 8 h, were the only regimens to attain optimal exposures against P aeruginosa. Ciprofloxacin had the lowest CFR against P aeruginosa, followed by cefepime. Among the P aeruginosa isolates collected in the intensive care unit (ICU) compared with the wards, differences of 0.5% to 10% were noted in favour of non-ICU isolates for all agents; however, marked differences (10% to 15%) in CFR were observed for ciprofloxacin in favour of ICU isolates.
CONCLUSION: Standard dosing of cefepime, doripenem, ertapenem and meropenem has a high likelihood of obtaining optimal pharmacodynamic indexes against these Enterobacteriaceae. For P aeruginosa, aggressive treatment with high-dose and/or prolonged infusion regimens are likely required to address the elevated resistance rates of respiratory isolates from Canada.
Authors:
Rebecca A Keel; George G Zhanel; Sheryl Zelenitsky; David P Nicolau
Related Documents :
24624034 - Prophylaxis with levofloxacin: impact on bacterial susceptibility and epidemiology in a...
23152524 - Hepatitis c virus variants with decreased sensitivity to direct-acting antivirals (daas...
8533024 - Characterization of paraguayan trypanosoma cruzi strains isolated from acute patients o...
22658314 - Molecular systematics in the genus mucor with special regards to species encountered in...
24713914 - Emergence of vim-2 metallo-beta-lactamase producing ralstonia pickettii clinical isolat...
1724154 - Surface-exposed antigenic determinants in outer membranes of wild yersinia pestis isola...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada     Volume:  22     ISSN:  1918-1493     ISO Abbreviation:  Can J Infect Dis Med Microbiol     Publication Date:  2011  
Date Detail:
Created Date:  2012-12-03     Completed Date:  2013-02-07     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101226876     Medline TA:  Can J Infect Dis Med Microbiol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  132-6     Citation Subset:  -    
Affiliation:
Center for Anti-Infective Research and Development, Connecticut, USA;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Mechanism of Variegation in immutans Provides Insight into Chloroplast Biogenesis.
Next Document:  Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococca...